Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Benitec Biopharma Inc.

Get SEC filing alerts via email and in your feed for Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company specializing in genetic medicines for treating serious genetic disorders. Its proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference with gene therapy to achieve sustained silencing of disease-causing genes and simultaneous replacement with functional wildtype genes. The company’s lead product candidate, BB-301, targets Oculopharyngeal Muscular Dystrophy (OPMD) using this “silence and replace" approach, aiming for durable therapeutic effects after a single administration.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Benitec Biopharma Inc.

1
1
Benitec Biopharma Inc. Benitec Biopharma Reports $11.9 Million Net Loss for Quarter, Advances BB-301 Clinical Trial

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Benitec Biopharma Inc. Benitec Biopharma Reports $20.8 Million Net Loss and Advances Clinical Trials for BB-301

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Benitec Biopharma Inc. Benitec Biopharma Reports $8.965 Million Net Loss and No Revenue for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Benitec Biopharma Inc. Benitec Biopharma Reports $1.2M Revenue Decline and $25.3M Net Loss in 2025

Via official filing (AI summary) | 8 months ago | 0 comments

5
1
Benitec Biopharma Inc. Benitec Biopharma Reports $9.4 Million Net Loss for Quarter Ended March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Benitec Biopharma Inc. Benitec Biopharma Reports $7.4 Million Net Loss in Q2 Fiscal 2025

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Benitec Biopharma Inc. Benitec Biopharma Reports Net Loss of $5.1M, Increased Cash Reserves in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments